ClinicalTrials.gg
CompletedNCT01404754MT-1Updated Oct 31, 2024

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

A Phase 1 interventional study of Lactose (inactive placebo) and midomafetamine HCl in Psychological Effects of Study Drug, sponsored by Lykos Therapeutics. Completed at 3 sites in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 3 months ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled Apr 2011, registered Jul 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to study MDMA-assisted therapy in healthy volunteers. The main question it aims to answer is:

Do two sessions of MDMA-assisted therapy result in changes in mood, emotional closeness to self and others, and other psychological symptoms?

Researchers will compare MDMA-assisted therapy to placebo with therapy.

Participants will have a non-drug preparatory session prior to each experimental session and an integrative session after each experimental session. Participants who received MDMA will crossover to receive placebo and placebo participants will crossover to receive MDMA.

Read the detailed description

This study is a Phase 1 study for up to a hundred people, The information gathered during this study may help us better understand the psychological effects produced by MDMA and how those effects can more effectively be used within a therapeutic context, as with people with PTSD. Participants will be healthy volunteers who have completed a program training them in conducting MDMA-assisted psychotherapy. In this randomized, double blind study, subjects will receive placebo and MDMA during two sessions scheduled at least two days apart in a psychotherapy setting. Mood, self-reported interpersonal closeness, psychological symptoms, blood pressure, heart rate and body temperature will be measured, and personality will be measured prior to the first therapy-like session and two months after the second session.

The study will follow a cross-over design, meaning that all participants will receive both MDMA and placebo, with order of session randomly assigned. Study participants will have a preparatory session prior to each experimental session and an integrative session after each session. The researchers will contact them via telephone one and two months after the second experimental session. By comparing changes in mood, feelings of emotional closeness to the self and others and psychological symptoms after placebo and after MDMA, the investigators hope to learn something about the effects of MDMA on mood, subjective experience and the way we think and feel about others.

02

Conditions studied

  • Psychological Effects of Study Drug

Keywords

  • MDMA
  • mood
  • subjective effects
  • interpersonal closeness
03

In context

Lead sponsor

Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Engaged in a sponsor-supported program for training therapists to perform MDMA-assisted psychotherapy research
  • Are at least 21 years old
  • Are willing to follow all rules and restrictions related to study participation, including restrictions on medication use for a week prior to experimental sessions and restrictions on food and alcohol consumption on the day prior to each experimental session
  • Are willing to remain overnight at the study site
  • Agree to have transportation other than driving themselves after the integrative session on the day after each experimental session
  • Are willing to be contacted via telephone for all necessary telephone contacts
  • If a woman of , must have a negative pregnancy test and agree to use an effective form of
  • Are proficient in speaking and reading English
  • Agree to have all clinic visit sessions recorded to audio and video

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of
  • Weigh less than 48 kg
  • Have used "ecstasy" (material represented as containing MDMA) within 6 months of the MDMA session
  • Require ongoing therapy with a psychotropic drug
  • Meet criteria for substance abuse or dependence for any substance
  • Unable to give adequate
  • Upon review of past and current drugs/medication must not be on or have taken a medication that is exclusionary
  • Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Placebo comparator
    Lactose (Inactive Placebo)

    Participant receives inactive placebo during day-long experimental session.

    Drug: Lactose (inactive placebo)

  • Active comparator
    3,4-methylenedioxymethamphetamine

    Participant receives 120 mg midomafetamine HCl possibly followed by 40 mg midomafetamine HCl during a day-long experimental session.

    Drug: midomafetamine HCl

Interventions

  • DrugLactose (inactive placebo)

    Placebo in an equivalent weight to midomafetamine HCl will be administered in identical appearing capsules during one of two experimental sessions. An equivalent to the initial and supplemental dose will exist.

    Also known as: placebo

  • 120 mg midomafetamine HCl will be administered in opaque capsules at the outside of one of two experimental sessions, and upon mutual agreement between the investigator and participant, 40 mg may be administered 1.5 to 2.5 hours later.

    Also known as: midomafetamine, MDMA, 3,4-methylenedioxymethamphetamine, MDMA HCl

06

What researchers measure

Primary outcomes

  1. Profile of Mood States (POMS)

    Assesses current mood state

    Time frame: Experimental session approximately six hours after drug administration

  2. Profile of Mood States (POMS)

    Assesses current mood state

    Time frame: Day prior to each experimental session

  3. Profile of Mood States (POMS)

    Assesses current mood state

    Time frame: Day after each experimental session

Secondary outcomes

  1. Interpersonal closeness measure

    Visual analog scale assessing emotional closeness to self and four other targets

    Time frame: Day prior to experimental session

  2. Interpersonal closeness measure

    Visual analog scale assessing emotional closeness to self and four other targets

    Time frame: Day of experimental session approximately six hours post-drug administration

  3. Interpersonal closeness measure

    Visual analog scale assessing emotional closeness to self and four other targets

    Time frame: Day after each experimental session

  4. Brief Symptom Inventory (BSI)

    Self-report measure assessing psychiatric symptoms

    Time frame: Day prior to each experimental session

  5. Brief Symptom Inventory (BSI)

    Self-report measure assessing psychiatric symptoms

    Time frame: Day of experimental session prior to drug administration

  6. Brief Symptom Inventory (BSI)

    Self-report measure assessing psychiatric symptoms

    Time frame: Day of experimental session approximately five to six hours after drug administration

  7. Brief Symptom Inventory (BSI)

    Self-report measure assessing psychiatric symptoms

    Time frame: Day after each experimental session

  8. Columbia Suicide Severity Rating Scale (adapted C-SSRS)

    Clinician-administered measure of suicide risk

    Time frame: Day prior to each experimental session

  9. Neuroticism Extroversion Openness Personality Inventory

    Self-report measure of five personality factors; Neuroticism, extroversion, openness to experience, conscientiousness and agreeableness

    Time frame: At baseline

  10. Neuroticism Extroversion Openness Personality Inventory

    Self-report measure of five personality factors; Neuroticism, extroversion, openness to experience, conscientiousness and agreeableness

    Time frame: Two months after the second experimental session

  11. Columbia Suicide Severity Rating Scale (adapted C-SSRS)

    Clinician-administered measure of suicide risk

    Time frame: Day after each experimental session

  12. Columbia Suicide Severity Rating Scale (adapted C-SSRS)

    Clinician-administered measure of suicide risk

    Time frame: One month after the second experimental session

  13. Columbia Suicide Severity Rating Scale (adapted C-SSRS)

    Clinician-administered measure of suicide risk

    Time frame: Two months after the second experimental session

  14. Columbia Suicide Severity Rating Scale (adapted C-SSRS)

    Clinician-administered measure of suicide risk

    Time frame: Day six and 12 of telephone contact after second experimental session

  15. Columbia Suicide Severity Rating Scale (adapted C-SSRS)

    Clinician-administered measure of suicide risk

    Time frame: Day of each experimental session prior to drug administration

  16. Columbia Suicide Severity Rating Scale (adapted C-SSRS)

    Clinician-administered measure of suicide risk

    Time frame: Day of each experimental session approximately five to six hours after drug administration

  17. Blood pressure (SBP/DBP)

    Periodic assessment of participant blood pressure during both experimental sessions.

    Time frame: Throughout each experimental session, every 15 minutes for 6 hours, then every 30 minutes for 2 hours

  18. Heart rate (pulse)

    Periodic assessment of participant pulse during both experimental sessions.

    Time frame: Throughout each experimental session, every 15 minutes for 6 hours, then every 30 minutes for 2 hours

  19. Body temperature

    Periodic assessment of participant body temperature during both experimental sessions.

    Time frame: Approximately every 60 minutes for each experimental session

07

Study locations

3 sites
  • Aguazul Bluewater, Inc.
    Boulder, Colorado 80304, United States
  • Santa Fe MDMA Therapy Training, LLC
    Santa Fe, New Mexico 87508, United States
  • Zen Therapeutic Solutions
    Mount Pleasant, South Carolina 29464, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2011 to primary completion in Aug 2022, 135 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2011
First posted
Jul 28, 2011
StartActual
Apr 9, 2011
Primary completionActual
Aug 5, 2022
CompletionActual
Aug 5, 2022
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01404754
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Jul 28, 2011
Start date
Apr 9, 2011
Primary completion
Aug 5, 2022
Completion
Aug 5, 2022
Last update
Oct 31, 2024

Study contacts

Michael M Mithoefer, MD
study director · Lykos Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion